DXNVX Appoints Yonggu Lee as New CEO and Kyu-chan Kwon as New President

DXVX announced on the 16th that it appointed Lee Yong-gu as the new CEO through a board meeting and recruited Kwon Kyu-chan, head of the Global Business Division at Hanmi Pharmaceutical, as president. The company plans to actively pursue the reorganization of its global distribution organization centered on sales veterans with over 30 years of experience, the launch of new products, and the strengthening of global new drug approval capabilities for its existing pipeline.

(From left) Yonggu Lee, new CEO, Kyuchan Kwon, new President. / Photo by DXNVX

New CEO Lee Yong-gu graduated from Hanyang University and joined Hanmi Pharmaceutical, where he served as team leader of sales and marketing strategy, laying the foundation for Hanmi’s diabetes and cardiovascular disease business. He also held positions such as General Manager of the Beijing Hanmi Pharmaceutical Management Planning Office, CEO of Beijing Lunmeikang Healthcare Division, and Vice President of COREE Group.

He is especially known as a global sales strategist who has successfully pioneered the pharmaceutical and healthcare business of Beijing Hanmi Pharmaceutical and COREE Group in China since 2006. In 2022, he led the growth of DXVX’s biohealthcare business, laying the groundwork for the resumption of trading. Recently, he has been highly evaluated for his contributions to securing growth engines for the company by planning the antibiotic distribution business and the launch of 12 microbiome-based products.

New President Kwon Kyu-chan holds a bachelor's and master's degree in Applied Biological Chemistry from Seoul National University and a Ph.D. in Technology Management Engineering from Korea University. He is a key figure in global pharmaceutical business, having worked at LG Chem Biotech Research Institute, LG Life Sciences Regulatory Affairs (RA) team, and served as head of the Global Business Division at Hanmi Pharmaceutical, overseeing overseas RA, overseas business development, overseas sales, new drug clinical trials, and licensing.

During his time at LG Life Sciences, he gained extensive experience in overseas approvals for vaccines such as quadrivalent vaccines, pentavalent vaccines, and meningitis vaccines. At Hanmi Pharmaceutical, he was a key player in obtaining FDA approval in the U.S. for ‘Rolvedon,’ the country’s first oncology bio new drug. Additionally, he led over 20 European approvals including for Hyaluma, Esomezol, Triyaxone, and Fidogle, as well as Japanese approval for Tamsulosin, holding the largest number of U.S. and European approvals in Korea. He also led more than 100 global pharmaceutical marketing authorizations worldwide. Furthermore, he has built a reputation as a top global pharmaceutical expert by securing over 150 IND approvals in global markets, obtaining FDA accelerated development program designations such as Fast Track for multiple new drug projects, and achieving the highest number of orphan drug designations in Korea.

Moreover, he has served as an adjunct professor at Korea University Graduate School of Engineering, advisor to the Korea Innovative Medicines Consortium (KimCo), advisory member for the Ministry of Food and Drug Safety’s biosimilar regulation establishment, member of the Korea Health Industry Development Institute’s global market development dispatch committee, and industry-academic cooperation professor at Daegu Catholic University. Currently, he is active as a member of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association’s Global Promotion Special Committee.

A DXVX official stated, “New CEO Lee Yong-gu is expected to drive the company’s rapid growth through strengthening domestic and international sales organizations and continuous global new product launches,” and added, “New President Kwon Kyu-chan, Korea’s top global pharmaceutical expert, plans to accelerate pipeline value enhancement through new drug development, global new drug approvals, and strategic alliances with big pharma.”

President Kwon Kyu-chan is scheduled to be appointed as an inside director after the upcoming shareholders’ meeting, while former CEO Park Sang-tae is designated as an inside director of Evicsgen, where he will continue to contribute to the company’s growth by advancing the new drug pipeline and expanding into the North American market.

Meanwhile, Han Sung-jun, appointed as CEO of Evicsgen, is an expert in infectious disease vaccines and new drug development from the Pasteur Institute. Park Sang-tae, designated as an inside director, holds a Ph.D. in microbiology and has recently served as CEO of DXVX, overseeing overall management, diagnostic technology development, vaccine business, and active R&D collaboration with overseas institutions.

This content was produced with the assistance of AI translation services.